• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Combined Impact of Surgery and Immunomodulation With Low Dose Cytoxan and GM-CSF in the Early Treatment of Breast Cancer
【24h】

Combined Impact of Surgery and Immunomodulation With Low Dose Cytoxan and GM-CSF in the Early Treatment of Breast Cancer

机译：手术和免疫调节与低剂量Cytoxan和Gm-CsF联合对乳腺癌早期治疗的影响

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The purpose of this study was to evaluate the combined impact of surgery and immunomodulation with low dose cytoxan and GM-CSF on the development of dendritic cells and the activation of T cells in vivo. MMTV Her2/neu mice, which spontaneously develop mammary tumors were treated with combinations of cytoxan, GM-CSF and surgery. Flow cytometry was used to evaluate blood (B), lymph nodal tissue (LN), and splenocytes (S) for evidence of monocyte differentiation to dendritic cells (DC). Both tumor naive mice and mice with spontaneous tumor growth were evaluated. With this study we were able to identify a subpopulation of monocytic cells with characteristics consistent with partial differentiation to dendritic cells using the cell surface markers CD11C, MHC II, CD86/CD40, CD80, and Ly6c. While this study was unable to demonstrate alteration of the cell surface markers of the monocytic cell populations in a manner consistent with dendritic cell differentiation using GM- CSF or cytoxan, this study suggests that the presence of tumor itself may alter the CD40 and MHC II level in the spleen and that the presence of tumor itself may lead to early differentiation of the dendritic cell population in the spleen.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号